Recruitment

Recruitment Status
Not yet recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • AIDS-related Kaposi Sarcoma
  • HIV Infection
  • Kaposi Sarcoma
Type
Interventional
Phase
Phase 1
Design
Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

OUTLINE: This is a dose-escalation study. Patients receive efineptakin alfa intramuscularly (IM) on day 1. Cycles repeat every 12 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up on day 7 and then e...

OUTLINE: This is a dose-escalation study. Patients receive efineptakin alfa intramuscularly (IM) on day 1. Cycles repeat every 12 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up on day 7 and then every 12 weeks for 15 months.

Tracking Information

NCT #
NCT04893018
Collaborators
Cancer Immunotherapy Trials Network
Investigators
Principal Investigator: Thomas S. Uldrick, MD, MS Fred Hutch/University of Washington Cancer Consortium